Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

“…It is interesting to note that it has been clearly demonstrated that SCIg replacement therapy involves lower costs than IVIg in subjects with PID, mainly due to the reduced need for Outpatient Clinic access. 38 In this regard, we would like to underline that, in our department, the shift from IVIg to SCIg significantly reduced the need of outpatients' visits related to hypogammaglobulinemia. During IVIg therapy, patients were forced to have monthly access for replacement therapy; but once SCIg treatment is well established, follow up for hypogammaglobulinemia basically required no more than one visit and one serum IgG test every three months.…”

Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy

“…Health economic aspects due to the switch from IVIG to SCIG have been studied and the conclusion is that SCIG is more cost effective than IVIG although it depends on the national healthcare system [19,20]. A recent cost-minimization analysis from Italy confirmed these findings [21].…”

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease

“…27 A 2005 cost analysis in Germany estimated that converting 60% of patients on IVIg to subcutaneous therapy would realize a savings of €17 to 77 million per year. 34 No study has taken into account the economic cost of missed hours from work or school, loss of productivity from untreated PIDD, additional costs of antibiotics or acute medical care, or the effect of the pricing structure of immunoglobulin on health care macroeconomics.…”